Video

Dr. Herzog on Impact of Recent Clinical Trials in Ovarian Cancer

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the impact of recent clinical trials in ovarian cancer.

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the impact of recent clinical trials in ovarian cancer.

Herzog says physicians owe all the progress observed in the treatment of patients with ovarian cancer to clinical trials. More than a decade ago, clinical trial data led to the adoption of paclitaxel-based chemotherapy into treatment, which has significantly improved outcomes. Phase III trials have also made a difference in allowing gynecologic oncologists to take a cumbersome inpatient regimen and turn it into a convenient outpatient regimen with the addition of carboplatin. Paclitaxel infusion time has also been adjusted from 24 hours to 3 hours.

Herzog adds that the GOG-178 trial showed an improvement of progression-free survival with maintenance therapy after paclitaxel-based chemotherapy for patients with advanced disease. Studies of dose-dense regimens are ongoing to see if patients can receive more therapy over a shorter period of time.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD